Thrasos Therapeutics Inc. announced in a press release the issuance of US patent number 7,482,329 covering a proprietary set of small molecules that selectively activate key receptors of the bone morphogenetic protein (BMP) family.
These compounds selectively activate the repair and regenerative effects of BMP without stimulating bone growth. This key differentiating factor offers significant potential for treating a broad range of life-threatening diseases and conditions, including Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD), the initial focus areas of the Company.
“Many researchers have sought to distinguish the activities of BMP through selective targeting of distinct receptors in the pathway,” Thrasos President and CEO Richard Andrews said.
“Thrasos has achieved a potentially field-changing breakthrough, generating a pipeline of first - in-class compounds that deliver anti-apoptotic, anti-inflammatory and anti-fibrotic effects without stimulating bone formation,” he added.
“Not only do these compounds have the ability to provide important clinical benefits, but they are also critical tools that will facilitate a more complete understanding of the BMP pathway and its receptors,” Andrews continued.
“We believe that our initial focus on kidney injury and disease allows us to target large markets that are currently not optimally addressed. We look forward to moving our lead AKI candidate into clinical testing within the next 12 months while pursuing partners for our CKD program and additional promising indications,” he stated.
“AKI and CKD are challenging medical conditions that can lead to increased risk of death and loss of kidney function. They are extremely costly to care for and present significant challenges to the medical community,” Chief Division of Nephrology, Stanford University School of Medicine Dr. Glenn Chertow commented.
“These compounds show significant promise in preventing and treating disease and have demonstrated consistently strong data in all studies to date. We are looking forward to seeing them in the clinical setting,” he elaborated.
Thrasos Therapeutics Inc. is a biotechnology company developing unique therapeutic agents to prevent and treat severe organ failure and other critical medical needs.
SOURCE:AGIPNEWS
